IBRANCE Home

IBRANCE is the first-in-class CDK4/6 inhibitor backed by two Phase 3 clinical trials and 3+ years in the market1,2
3+ years
since initial FDA approval
11,500+ prescribers
have chosen IBRANCE3*
75,000+ patients
prescribed IBRANCE3*
TWO CATEGORY 1 RECOMMENDATIONS FROM
THE NATIONAL COMPREHENSIVE CANCER NETWORK
®4
Palbociclib (IBRANCE) + aromatase inhibitor
may be considered as a treatment option for first-line therapy for postmenopausal women with HR+/HER2- MBC
Palbociclib (IBRANCE) + fulvestrant
for postmenopausal women or premenopausal women receiving ovarian suppression with an LHRH agonist with HR+/HER2- MBC that has progressed on or after prior adjuvant or metastatic endocrine therapy
Category 1: Based on high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.4
If there is disease progression while on CDK4/6 inhibitor therapy, there are no data to support an additional line of therapy with another CDK4/6-containing regimen.4
*Data projected as of January 2018.3
CDK4/6=cyclin-dependent kinases 4 and 6; LHRH=luteinizing hormone-releasing hormone; MBC=metastatic breast cancer; NCCN®=National Comprehensive Cancer Network®.
REFERENCES
1. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925-1936.
2. Turner NC, Ro J, Andre F, et al; PALOMA3 Study Group. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209-219.
3. Data on file. Pfizer Inc, New York, NY.
4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.1.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed April 13, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.